| 2006 |
Reginster J-Y, Burlet N. Osteoporosis: a still increasing prevalence. Bone. February 2006;38(2)(suppl 1):4-9. |
39 |
38 |
| 2020 |
Ladang A, Beaudart C, Locquet M, Reginster J-Y, Bruyère O, Cavalier E. Evaluation of a panel of microRNAs that predicts fragility fracture risk: a pilot study. Calcif Tiss Int. March 2020;106(3):239-247. |
1 |
1 |
| 2012 |
Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwiński E, Krieg M-A, Man Z, Mellström D, Radominski SC, Reginster J-Y, Resch H, Ivorra JAR, Roux C, Vittinghoff E, Austin M, Daizadeh N, Bradley MN, Grauer A, Cummings SR, Bone HG. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. March 2012;27(3):694-701. |
17 |
10 |
| 2019 |
Ferrari S, Libanati C, Lin CJF, Brown JP, Cosman F, Czerwiński E, de Gregόrio LH, Malouf-Sierra J, Reginster J-Y, Wang A, Wagman RB, Lewiecki EM. Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment. J Bone Miner Res. June 2019;34(6):1033-1040. |
12 |
9 |
| 2017 |
Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster J-Y, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. July 2017;5(7):513-523. |
48 |
36 |
| 2001 |
McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Wasnich RD, Greenwald M, Kaufman J-M, Chesnut CH, Reginster J-Y; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group. NEJM. February 1, 2001;344(5):333-340. |
73 |
56 |
| 2001 |
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mellström D, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki AZ, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. NEJM. May 10, 2001;344(19):1434-1441. |
162 |
150 |
| 2014 |
McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster J-Y, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang Y-C, Libanati C, Bone HG. Romosozumab in postmenopausal women with low bone mineral density. NEJM. January 30, 2014;370(5):412-420. |
78 |
66 |
| 2000 |
Reginster J-Y, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R; Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. January 2000;11(1):83-91. |
73 |
62 |
| 2008 |
Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster J-Y, Borgstrom F, Rizzoli R; European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. April 2008;19(4):399-428. |
16 |
10 |
| 2013 |
Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO); Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. January 2013;24(1):23-57. |
26 |
16 |
| 2015 |
Papapoulos S, Lippuner K, Roux C, Lin CJF, Kendler DL, Lewiecki EM, Brandi ML, Czerwiński E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster JY, Jensen S, Daizadeh NS, Wang A, Gavin M, Libanati C, Wagman RB, Bone HG. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study. Osteoporos Int. December 2015;26(12):2773-2783. |
22 |
15 |
| 2017 |
Harvey NCW, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster J-Y, Rizzoli R, Cooper C, Kanis JA. Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int. May 2017;28(5):1507-1529. |
15 |
5 |
| 2019 |
Kanis JA, Cooper C, Rizzoli R, Reginster J-Y; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO); Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. January 2019;30(1):3-44. |
63 |
47 |
| 2020 |
Kanis JA, Harvey NC, McCloskey E, Bruyère O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, Al-Daghri N, Campusano C, Chandran M, Dawson-Hughes B, Javaid K, Jiwa F, Johansson H, Lee JK, Liu E, Messina D, Mkinsi O, Pinto D, Prieto-Alhambra D, Saag K, Xia W, Zakraoui L, Reginster J-Y. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. January 2020;31(1):1-12. |
12 |
7 |
| 2020 |
Chiu W-Y, Lin C-J, Yang W-S, Tsai K-S, Reginster J-Y. Racial difference in bioavailability of oral ibandronate between Caucasian and Taiwanese postmenopausal women. Osteoporos Int. January 2020;31(1):193-201. |
0 |
0 |
| 2020 |
Kanis JA, Cooper C, Rizzoli R, Reginster J-Y; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO); Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). Correction to “European guidance for the diagnosis and management of osteoporosis in postmenopausal women”. Osteoporos Int. January 2020;31(1):209-209. |
0 |
0 |
| 2020 |
Geiker NRW, Mølgaard C, Iuliano S, Rizzoli R, Manios Y, van Loon LJC, Lecerf J-M, Moschonis G, Reginster J-Y, Givens I, Astrup A. Impact of whole dairy matrix on musculoskeletal health and aging: current knowledge and research gaps [published correction appears in Osteoporos Int. April 2020;31(4):795-795]. Osteoporos Int. April 2020;31(4):601-615. |
0 |
0 |
| 2020 |
Geiker NRW, Mølgaard C, Iuliano S, Rizzoli R, Manios Y, van Loon LJC, Lecerf J-M, Moschonis G, Reginster J-Y, Givens I, Astrup A. Correction to: impact of whole dairy matrix on musculoskeletal health and aging: current knowledge and research gaps. Osteoporos Int. April 2020;31(4):795-795. |
0 |
0 |
| 2020 |
Kanis JA, Harvey NC, McCloskey E, Bruyère O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, Al-Daghri N, Campusano C, Chandran M, Dawson-Hughes B, Javaid K, Jiwa F, Johansson H, Lee JK, Liu E, Messina D, Mkinsi O, Pinto D, Prieto-Alhambra D, Saag K, Xia W, Zakraoui L, Reginster JY. Correction to: algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. April 2020;31(4):797-798. |
0 |
0 |
| 2020 |
Kanis JA, Cooper C, Rizzoli R, Reginster J-Y; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO); Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). Correction to: European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. April 2020;31(4):801-801. |
0 |
0 |
| 2020 |
Cornelissen D, Kunder Sd, Si L, Reginster J-Y, Evers S, Boonen A, Hiligsmann M; European Society for Clinical and Economic Aspect of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review. Osteoporos Int. September 2020;31(9):1645-1669. |
1 |
1 |
| 2020 |
Kanis JA, Cooper C, Dawson-Hughes B, Harvey NC, Johansson H, Lorentzon M, McCloskey EV, Reginster J-Y, Rizzoli R; International Osteoporosis Foundation. FRAX and ethnicity. Osteoporos Int. November 2020;31(11):2063-2067. |
0 |
0 |
| 2020 |
McClung MR, Bolognese MA, Brown JP, Reginster J-Y, Langdahl BL, Maddox J, Shi Y, Rojeski M, Meisner PD, Grauer A. A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. Osteoporos Int. November 2020;31(11):2231-2241. |
1 |
1 |
| 2020 |
Rozenberg S, Al-Daghri N, Aubertin-Leheudre M, Brandi M-L, Cano A, Collins P, Cooper C, Genazzani AR, Hillard T, Kanis JA, Kaufman J-M, Lambrinoudaki I, Laslop A, McCloskey E, Palacios S, Prieto-Alhambra D, Reginster J-Y, Rizzoli R, Rosano G, Trémollieres F, Harvey NC. Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis? Osteoporos Int. December 2020;31(12):2271-2286. |
1 |
1 |
| 2021 |
Chandran M, Ganesan G, Tan KB, Reginster J-Y, Hiligsmann M. Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women. Osteoporos Int. January 2021;32(1):133-144. |
0 |
0 |
| 2021 |
Hiligsmann M, Maggi S, Veronese N, Sartori L, Reginster J-Y. Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in iItaly. Osteoporos Int. March 2021;32(3):595-606. |
0 |
0 |
| 2021 |
Cooper C, Halbout P, Dawson-Hughes B, Harvey NC, Kanis JA, Reginster J-Y, Rizzoli R. In memory of Harry K Genant. Osteoporos Int. March 2021;32(3):607-608. |
0 |
0 |
| 2021 |
Fuggle NR, Singer A, Gill C, Patel A, Medeiros A, Mlotek AS, Pierroz DD, Halbout P, Harvey NC, Reginster J-Y, Cooper C, Greenspan SL. How has COVID-19 affected the treatment of osteoporosis? an IOF-NOF-ESCEO global survey. Osteoporos Int. April 2021;32(4):611-617. |
3 |
2 |
| 2021 |
Chandran M, Ganesan G, Tan KB, Reginster J-Y, Hiligsmann M. Using health-economic evidence to support policy-level decision-making in Singapore: sensitivity analysis that provides further confidence in fracture probability-based cost-effective intervention thresholds. Osteoporos Int. April 2021;32(4):787-789. |
0 |
0 |
| 2021 |
Fuggle NR, Singer A, Gill C, Patel A, Medeiros A, Mlotek AS, Pierroz DD, Halbout P, Harvey NC, Reginster J-Y, Cooper C, Greenspan SL. Correction to: How has COVID-19 affected the treatment of osteoporosis? an IOF-NOF-ESCEO global survey. Osteoporos Int. April 2021;32(4):801-801. |
1 |
0 |